Mapping micrometastatic seeds of relapse.

Hui Ting Grace Yeo; Iain Beehuat Tan

doi:10.1016/j.ccell.2026.07.007

Home/Archive/PubMed

PubMed · 42537651

Mapping micrometastatic seeds of relapse.

Hui Ting Grace Yeo·Iain Beehuat Tan

View original source ↗Export metadata ↓

Abstract

In this issue of Cancer Cell, Liu et al. apply spatial multi-omics to map colorectal cancer micrometastases across primary tumors and matched liver and lung metastases, revealing liver micrometastases as an early evolved, stem-like, immune-suppressed residual disease state linked to a six-gene recurrence signature.

Explore related subjects

Colorectal Neoplasms Neoplasm Metastasis Humans Multiomics Liver Neoplasms Lung Neoplasms Neoplastic Processes Journal Article Comment

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hui Ting Grace Yeo, Iain Beehuat Tan. 2026-07-31. Mapping micrometastatic seeds of relapse.. https://doi.org/10.1016/j.ccell.2026.07.007

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Co-targeting Deregulated WNT and MAPK Signaling Pathways Limits Phenotypic Reprogramming of Intestinal Stem Cell Progeny in KRAS-Hyperactivated Colorectal Cancer.

In their recent article, Moore and colleagues demonstrate that, upon KRAS hyperactivation, colorectal cancer growth is driven by a reprogramming of Lgr5+ intestinal stem cell (ISC) progeny towards the acquisition of a regenerative phenotype. They find that this phenotype is regulated by a balance between WNT-related ISCs and MAPK-related regenerative and proliferative transcriptional programs. By targeting both pathways, they are able to suppress this dynamic plasticity and achieve tumor regression in cell line and mouse models. The antagonistic relationship between these central pathways defined here provides key insights into genomic patterns of colorectal cancer and targeted therapy strategies.

Colorectal Neoplasms↗

PubMed2026

Identification and validation of a previously missed mutational signature in colorectal cancer.

Mutational signature analysis has enhanced our understanding of mutagenic processes. In a recent study, we analyzed 802 microsatellite-stable colorectal cancers (CRC) and identified a de novo signature, SBS_D, which was decomposed into SBS18. Here, we re-evaluate this decomposition and provide evidence that SBS_D represents a distinct mutational process from SBS18. Through an analysis of 2,616 CRCs across three independent cohorts, we demonstrate that SBS_D is consistently present, suggesting this signature may have been previously overlooked. We illustrate that the pattern of SBS_D better aligns with signatures associated with deficiencies in DNA repair, despite evidence that SBS_D is not driven by canonical defects in these DNA repair pathways. Overall, this study identifies a previously unrecognized mutational signature in DNA repair-proficient CRC and proposes that its etiology may be linked to DNA repair infidelity emerging late in tumor development. SBS_D has been submitted to the COSMIC database and provisionally designated as SBS111.

Colorectal Neoplasms↗

PubMed2026

To unveil the causal relationship between immunophenotypes and colorectal cancer using two-sample bidirectional Mendelian randomization and mediation analyses.

Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. The mechanisms underlying this trend are not yet fully understood. This study aimed to examine the potential role of genetically predicted immunophenotypes in the development of CRC. A two-sample bidirectional Mendelian randomization study was conducted to explore the relationship between 731 genetically predicted immune cells and CRC. Furthermore, a two-step Mendelian randomization approach was employed to assess the possible mediating effect of immune cells on CRC. The inverse-variance weighted method identified 5 immunophenotypes as significantly inversely associated with CRC risk: the odds ratios for CRC risk associated with activated CD4 regulatory T cells (%CD4 regulatory T cells), CD25++ CD45RA- CD4 nonregulatory T cells (%CD4 + T cells), CD25++ CD45RA- CD4 nonregulatory T cells (%T cells), CD25++ CD8 + T cells (%T cells), and CD64 + CD16 + monocytes were 0.925 (95% CI = 0.874-0.978, P = 6.516 × 10-3), 0.935 (95% CI = 0.878-0.995, P = .035), 0.936 (95% CI = 0.889-0.985, P = .011), 0.863 (95% CI = 0.786-0.948, P = 2.142 × 10-3), and 0.636 (95% CI = 0.519-0.778, P = 1.18 × 10-5), respectively. The mediation analysis indicated that the absolute count of CD25++ CD8 + T cells led to a 33.9% decrease in the risk associated with the percentage of activated CD4 regulatory T cells within CD4 regulatory T cells and CRC. Our analysis revealed that 5 immunophenotypes may be risk factors for CRC. Since other complementary methods have yielded inconsistent results, however, further investigation is necessary.

Colorectal Neoplasms↗